Evidence map›Paper›PMID 41499446›Full record

ArticleJNCI cancer spectrum2026

Risk of late recurrence of colorectal and breast cancer among older long-term cancer survivors.

Faiza Yasin, Sarah J Westvold, Jessica B Long, Terry Hyslop, Michael Cecchini, Ira Leeds, Andrea Silber, Shi-Yi Wang, Lisa Spees, Rebecca Forman and 4 more

Abstract read
In one paragraph

Article in JNCI cancer spectrum, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

14 authors.

Faiza YasinDepartment of Medicine (Medical Oncology), Yale School of Medicine, New Haven, CT, United States.ORCID 0000-0003-3042-0826
Sarah J WestvoldYale Cancer Outcomes, Public Policy and Effectiveness Research (COPPER) Center, New Haven, CT, United States.ORCID 0009-0004-2060-2137
Jessica B LongYale Cancer Outcomes, Public Policy and Effectiveness Research (COPPER) Center, New Haven, CT, United States.
Terry HyslopSidney Kimmel Comprehensive Cancer Center, Thomas Jefferson University, Philadelphia, PA, United States.ORCID 0000-0002-3930-8876
Michael CecchiniDepartment of Medicine (Medical Oncology), Yale School of Medicine, New Haven, CT, United States.ORCID 0000-0003-3504-0128
Ira LeedsYale Cancer Outcomes, Public Policy and Effectiveness Research (COPPER) Center, New Haven, CT, United States.ORCID 0000-0001-6572-8658
Andrea SilberDepartment of Medicine (Medical Oncology), Yale School of Medicine, New Haven, CT, United States.ORCID 0000-0002-3339-6959
Shi-Yi WangYale Cancer Outcomes, Public Policy and Effectiveness Research (COPPER) Center, New Haven, CT, United States.ORCID 0000-0002-3294-5784
Lisa SpeesLineberger Comprehensive Cancer Center (UNC-CH), Chapel Hill, NC, United States.ORCID 0000-0002-5680-9330
Rebecca FormanDepartment of Medicine (Medical Oncology), Yale School of Medicine, New Haven, CT, United States.
Tendai KwarambaDepartment of Medicine (Medical Oncology), Yale School of Medicine, New Haven, CT, United States.ORCID 0009-0003-8473-3550
Melissa TaylorDepartment of Medicine (Medical Oncology), Yale School of Medicine, New Haven, CT, United States.ORCID 0000-0002-2629-978X
Cary P GrossYale Cancer Outcomes, Public Policy and Effectiveness Research (COPPER) Center, New Haven, CT, United States.ORCID 0000-0002-4974-935X
Michaela A DinanYale Cancer Outcomes, Public Policy and Effectiveness Research (COPPER) Center, New Haven, CT, United States.ORCID 0000-0003-4849-4743

Funding

American Cancer SocietyRSG-21-039-01
6 · The paper itself

Abstract

backgroundA growing population of older adult cancer survivors faces competing cancer and noncancer health risks. There are limited real-world data on recurrence patterns beyond 5 years post-treatment.

methodsThis was a SEER-Medicare retrospective cohort study of patients aged ≥66 with stage I-III breast, colon, or rectal cancer who received definitive surgery and survived ≥5 years from diagnosis without recurrence or second primary malignancy. Late recurrence (5-10 years postdiagnosis) was identified using a validated algorithm to detect treated recurrence in Medicare claims. Demographic and clinical characteristics collected at cancer diagnosis were assessed as predictors of late treated recurrence using restricted mean survival time (RMST) regression.

resultsThe sample included 12 859 breast, 17 329 colon, and 4427 rectal cancer survivors. The cumulative incidence of late treated recurrence 5-10 years postdiagnosis was 5.0% in breast, 4.4% in colon, and 8.0% in rectal cancer survivors. In all cohorts, stage was associated with shorter RMST. The absolute risk difference between stage I and III was greatest in breast (2% vs 18.1%), followed by rectal (5.2% vs 10.3%) and colon (2.7% vs 6.7%) cancer survivors (P < .001 for all cohorts). Although their effect on RMST was modest (<5%), higher grade, node-positive, and ER-positive disease in breast, left-sided tumors in colon, and radiation in rectal cancer were associated with late treated recurrence. Across all cohorts, the incidence of other-cause mortality (24.1%-34.0%) exceeded cancer-specific mortality (2.9%-6.2%).

conclusionsLate treated recurrence in older long-term survivors is uncommon, but risk remains elevated 5 years postdiagnosis in those with more advanced stage.

Indexed as

Breast NeoplasmsCancer SurvivorsColonic NeoplasmsNeoplasm Recurrence, LocalRectal NeoplasmsAdministrative Claims, HealthcareAgedAged, 80 and overFemaleFollow-Up StudiesHumansIncidenceMaleMedicareNeoplasm StagingRetrospective Studies

Identifiers

PMID41499446
PMCPMC13158798

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.